A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Small Cell Lung Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Has histologically or cytologically confirmed diagnosis of Extensive-Stage Small Cell Lung Cancer in need of first-line therapy. 2. Has extensive-stage Small Cell Lung Cancer defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition.

You may not be eligible for this study if the following are true:

  • 1. Has had major surgery within 3 weeks before first dose of study interventions. 2. Has a preexisting =Grade 3 gastrointestinal or non-gastrointestinal fistula. 3. Has urine protein =1 g/24 hours.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.